Association of Tocilizumab and Invasive Aspergillosis in Critically Ill Patients with Severe COVID-19 Pneumonia and Acute Respiratory Distress Syndrome

被引:3
作者
Wu, Kuo-Lun [1 ]
Chang, Chia-Yuan [2 ]
Sung, Heng-You [2 ]
Hu, Ting-Yu [3 ,4 ]
Kuo, Li-Kuo [3 ,4 ]
机构
[1] Mackay Mem Hosp, Div Pulm & Crit Care Med, Taipei 10449, Taiwan
[2] Mackay Mem Hosp, Dept Internal Med, Taipei 10449, Taiwan
[3] Mackay Mem Hosp, Dept Crit Care Med, Taipei 10449, Taiwan
[4] Mackay Med Coll, Dept Med, New Taipei 25245, Taiwan
关键词
acute respiratory distress syndrome; COVID-19-associated pulmonary aspergillosis; tocilizumab;
D O I
10.3390/jof8040339
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Coronavirus disease-2019 (COVID-19) causes severe pneumonia and acute respiratory distress syndrome. According to the current consensus, immunosuppressants, such as dexamethasone and anti-interleukin-6 receptor monoclonal antibodies, are therapeutic medications in the early stages of infection. However, in critically ill patients, viral, fungal, and bacterial coinfection results in higher mortality. We conducted a single-center, retrospective analysis of 29 mechanically ventilated patients with artificial airways. Patients were adults with confirmed COVID-19 infection and severe pneumonia. Acute respiratory distress syndrome was diagnosed according to the Kigali modification of the Berlin definition. Six patients had invasive pulmonary aspergillosis coinfection based on elevated serum galactomannan levels and/or bronchoalveolar lavage fluid. We present two cases with brief histories and available clinical data. We also conducted a literature review to determine whether immunosuppressants, such as tocilizumab, increase infection risk or invasive aspergillosis in patients with COVID-19. There is no conclusive evidence to suggest that tocilizumab increases coinfection risk. However, further studies are needed to determine the optimal dose, between-dose interval, and timing of tocilizumab administration in patients with COVID-19.
引用
收藏
页数:9
相关论文
共 24 条
  • [1] Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
    Angriman, Federico
    Ferreyro, Bruno L.
    Burry, Lisa
    Fan, Eddy
    Ferguson, Niall D.
    Husain, Shahid
    Keshavjee, Shaf H.
    Lupia, Enrico
    Munshi, Laveena
    Renzi, Samuele
    Ubaldo, Onion Gerald, V
    Rochwerg, Bram
    Del Sorbo, Lorenzo
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (06) : 655 - 664
  • [2] Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with β-lactam antibiotics in patients with hematological disorders
    Aubry, A
    Porcher, R
    Bottero, J
    Touratier, S
    Leblanc, T
    Brethon, B
    Rousselot, P
    Raffoux, E
    Menotti, J
    Derouin, F
    Ribaud, P
    Sulahian, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (02) : 389 - 394
  • [3] Burger B.J., 2021, TOCILIZUMAB IS ASS I, pA2635
  • [4] A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
    Cai, Shaozhe
    Sun, Wei
    Li, Ming
    Dong, Lingli
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (09) : 2797 - 2802
  • [5] Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
    Deana, Cristian
    Vetrugno, Luigi
    Bassi, Flavio
    De Monte, Amato
    [J]. MEDICAL MYCOLOGY CASE REPORTS, 2021, 31 : 32 - 34
  • [6] Serum Galactomannan-Based Early Detection of Invasive Aspergillosis in Hematology Patients Receiving Effective Antimold Prophylaxis
    Duarte, Rafael F.
    Sanchez-Ortega, Isabel
    Cuesta, Isabel
    Arnan, Montserrat
    Patino, Beatriz
    Fernandez de Sevilla, Alberto
    Gudiol, Carlota
    Ayats, Josefina
    Cuenca-Estrella, Manuel
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 59 (12) : 1696 - 1702
  • [7] Tocilizumab in patients with severe COVID-19: a retrospective cohort study
    Guaraldi, Giovanni
    Meschiari, Marianna
    Cozzi-Lepri, Alessandro
    Milic, Jovana
    Tonelli, Roberto
    Menozzi, Marianna
    Franceschini, Erica
    Cuomo, Gianluca
    Orlando, Gabriella
    Borghi, Vanni
    Santoro, Antonella
    Di Gaetano, Margherita
    Puzzolante, Cinzia
    Carli, Federica
    Bedini, Andrea
    Corradi, Luca
    Fantini, Riccardo
    Castaniere, Ivana
    Tabbi, Luca
    Girardis, Massimo
    Tedeschi, Sara
    Giannella, Maddalena
    Bartoletti, Michele
    Pascale, Renato
    Dolci, Giovanni
    Brugioni, Lucio
    Pietrangelo, Antonello
    Cossarizza, Andrea
    Pea, Federico
    Clini, Enrico
    Salvarani, Carlo
    Massari, Marco
    Viale, Pier Luigi
    Mussini, Cristina
    [J]. LANCET RHEUMATOLOGY, 2020, 2 (08) : E474 - E484
  • [8] IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections
    Kimmig, Lucas M.
    Wu, David
    Gold, Matthew
    Pettit, Natasha N.
    Pitrak, David
    Mueller, Jeffrey
    Husain, Aliya N.
    Mutlu, Ece A.
    Mutlu, Gokhan M.
    [J]. FRONTIERS IN MEDICINE, 2020, 7
  • [9] Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
    Koehler, Philipp
    Bassetti, Matteo
    Chakrabarti, Arunaloke
    Chen, Sharon C. A.
    Colombo, Arnaldo Lopes
    Hoenigl, Martin
    Klimko, Nikolay
    Lass-Florl, Cornelia
    Oladele, Rita O.
    Vinh, Donald C.
    Zhu, Li-Ping
    Boll, Boris
    Bruggemann, Roger
    Gangneux, Jean-Pierre
    Perfect, John R.
    Patterson, Thomas F.
    Persigehl, Thorsten
    Meis, Jacques F.
    Ostrosky-Zeichner, Luis
    White, P. Lewis
    Verweij, Paul E.
    Cornely, Oliver A.
    [J]. LANCET INFECTIOUS DISEASES, 2020, 21 (06) : E149 - E162
  • [10] COVID-19 Associated Pulmonary Aspergillosis: Diagnostic Performance, Fungal Epidemiology and Antifungal Susceptibility
    Lackner, Nina
    Thome, Claudius
    Oefner, Dietmar
    Joannidis, Michael
    Mayerhoefer, Timo
    Arora, Rohit
    Samardzic, Eldina
    Posch, Wilfried
    Breitkopf, Robert
    Lass-Floerl, Cornelia
    [J]. JOURNAL OF FUNGI, 2022, 8 (02)